Compugen Ltd. Ordinary Shares (CGEN)
Stock · NASDAQ · Health Care
$1.95as of 10/16/2026
Price chart
Active signals
CGEN Signal Track Record
How signals performed across all stocks →What CGEN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -3.0% | 37% | September 15, 2026 |
| Bollinger Band Breakout | 24 | -3.7% | 42% | August 12, 2026 |
| Bollinger Band Breakdown | 19 | 0.0% | 47% | October 6, 2026 |
| 200-Day Moving Average TouchActive now | 16 | -2.5% | 44% | June 10, 2026 |
| Any 20-session window (baseline) | -2.4% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CGEN
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been eval…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 75
- Website
- cgen.com/
Fundamentals
- 1-day range
- $1.93$2.09
- Market cap
- $217.54M
- P/E (trailing)
- 5.59
- P/E (forward)
- -5.35
- EPS (trailing)
- $0.36
- Dividend yield
- —
- Beta
- 2.78
- Avg. volume
- 242.4K
Forecasts
5 analyst ratings
Compugen Ltd. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- CGENCompugen Ltd. Ordinary Shares$1.96▼ 5.77%Market cap $217.54MP/E 5.59$1.43$3.24
- TARAProtara Therapeutics Inc. Common Stock$2.32▼ 3.33%Market cap $230.44MP/E —$2.38$7.82
- ALECAlector Inc. Common Stock$1.84▼ 3.66%Market cap $203.18MP/E —$1.09$3.4
- PLXProtalix BioTherapeutics Inc. (DE) Common Stock$2.62▼ 2.96%Market cap $196.59MP/E 11.27$1.6$3.19
- CHRSCoherus Oncology Inc. Common Stock$0.99▼ 7.48%Market cap $195.13MP/E —$1.01$2.62
- IVVDInvivyd Inc. Common Stock$0.619▼ 7.47%Market cap $194.15MP/E —$0.5277$3.07
- DTILPrecision BioSciences Inc. Common Stock$5.77▼ 6.48%Market cap $191.45MP/E —$3.53$9.62
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CGEN Compugen Ltd. Ordinary Shares | $217.54M | 5.59 | $1.96 | ▼ 5.77% | $1.43$3.24 |
| TARA Protara Therapeutics Inc. Common Stock | $230.44M | — | $2.32 | ▼ 3.33% | $2.38$7.82 |
| ALEC Alector Inc. Common Stock | $203.18M | — | $1.84 | ▼ 3.66% | $1.09$3.4 |
| PLX Protalix BioTherapeutics Inc. (DE) Common Stock | $196.59M | 11.27 | $2.62 | ▼ 2.96% | $1.6$3.19 |
| CHRS Coherus Oncology Inc. Common Stock | $195.13M | — | $0.99 | ▼ 7.48% | $1.01$2.62 |
| IVVD Invivyd Inc. Common Stock | $194.15M | — | $0.619 | ▼ 7.47% | $0.5277$3.07 |
| DTIL Precision BioSciences Inc. Common Stock | $191.45M | — | $5.77 | ▼ 6.48% | $3.53$9.62 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- HC Wainwright & Co. Reiterates Buy on Compugen, Maintains $4 Price Targetbenzinga · 10/12/2026
- Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development ConferenceYahoo · 10/6/2026
- Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor TargetsYahoo · 10/5/2026
- Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements TranscriptSeekingAlpha · 10/5/2026
- Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026Yahoo · 9/22/2026
Insider Activity
Insider Actions →- Michelle Mahler · July 29, 2026 · Grant13.5K
- Zurit Levine · July 29, 2026 · Grant24.0K
- Zurit Levine · July 29, 2026 · Grant18.0K
- David Silberman · July 29, 2026 · Grant26.0K
- David Silberman · July 29, 2026 · Grant19.5K
- Eran Ophir · July 29, 2026 · Grant200.0K
- Cohen-Dayag Anat · July 29, 2026 · Grant100.0K
- Eran Perry · July 29, 2026 · Grant10.0K
- Eran Perry · July 29, 2026 · Grant7.5K
- Ferre Pierre · July 29, 2026 · Grant70.0K
- Russo Sharon Kredo · July 29, 2026 · Grant24.0K
- Russo Sharon Kredo · July 29, 2026 · Grant18.0K
- Savitzky Kinneret Livnat · July 29, 2026 · Grant10.0K
- Savitzky Kinneret Livnat · July 29, 2026 · Grant7.5K
- Mathias Hukkelhoven · July 29, 2026 · Grant10.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Compugen to Host Virtual KOL Event on COM701
Compugen announced it will host a virtual event on October 5, 2026, to discuss its COM701 program in ovarian cancer and updates on the Unigen platform. This event is relevant as it provides a platform for the company to share scientific data with key opinion leaders. The stock currently trades below its average analyst target, with technical indicators showing it is near support levels.
Compugen to Host Virtual KOL Event on COM701. Compugen announced it will host a virtual event on October 5, 2026, to discuss its COM701 program in ovarian cancer and updates on the Unigen platform. This event is relevant as it provides a platform for the company to share scientific data with key opinion leaders. The stock currently trades below its average analyst target, with technical indicators showing it is near support levels.